Ugur Ozerdem, M.D.
Associate Professor
La Jolla Bioengineering Institute
La Jolla, CA
email

  

 

 

 

 

EDUCATION

2000-2002

Postdoctoral Fellowship, The Burnham Institute for Medical Research, San Diego

1998-2000

 Retina–Vitreous Diseases and Surgery Fellowship, UCSD Shiley Eye Center, San Diego

1993-1997

 Ophthalmology Residency, Hacettepe University School of Medicine, Ankara

1986-1993

 M.D., Hacettepe University School of Medicine, Ankara

EXPERIENCE 

12/2007-Present

Associate Professor, La Jolla Bioengineering Institute, La Jolla, CA

9/2003-12/2007

Assistant Professor, La Jolla Institute for Molecular Medicine, San Diego

3/2002-9/2003

Research Assistant Professor, The Burnham Institute for Medical Research, San Diego

HONORS AND MEMBERSHIPS  

2008

Study Section member, American Heart Association (AHA), Western States Research Consortium
2007 Distinguished Lecturer, M. D. Anderson Cancer Center in Houston, Texas
2007-Present Scientific Referee of Journal of Bone and Joint Surgery
2007-Present Scientific Referee of Biotechnology and Bioengineering
2006-Present Scientific Referee of Cancer Letters

(2006), NF-A

Study Section member, Neurofibromatosis Research Program CDMRP-Department of Defense

(2006), NF- IIRA

Study Section member, Neurofibromatosis Research Program CDMRP-Department of Defense

2006-Present

Scientific Referee of American Journal of Physiology-Heart and Circulatory Physiology

2006-Present

Scientific Referee of Clinical and Experimental Ophthalmology

2006-Present

Scientific Referee of Journal of Molecular Biology (JMB)

2005

Elected F.A.H.A. (Fellow, American Heart Association)

(2005), NF-A

Study Section member, Neurofibromatosis Research Program CDMRP-Department of Defense

2005-Present

Scientific Referee of Arteriosclerosis, Thrombosis, and Vascular Biology journal of AHA

2003-Present

Scientific Referee of Investigative Ophthalmology and Visual Sciences journal of ARVO

1999-Present

Scientific Referee of Ophthalmology journal of American Academy of Ophthalmology

2005-Present

Scientific Referee of The Journal of Clinical Investigation (JCI)

American Heart Association (AHA) New Investigator Award in AHA-ATVB Conference

PUBLICATIONS

  1. Ozerdem, U. 2006 Targeting pericytes diminishes neovascularization in orthotopic uveal melanoma in                 nerve/glial antigen 2 proteoglycan knockout mouse. Ophthalmic Res. 38(5):251-4.

  2. Ozerdem, U. 2006. Targeting of Pericytes Diminishes Neovascularization and Lymphangiogenesis in Prostate Cancer. The Prostate 66(3):294-304. 

  3. Ueda, E., U. Ozerdem, Y. Chen, M. Yao, K.T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A.M. Walker. 2006. A molecular mimic demonstrates that phosphorylated human prolactin is a potent antiangiogenic hormone. Endocrine-related Cancer 13(1):95-111.

  4. Ozerdem, U., K. Alitalo, P. Salven, and A. Li. 2005. Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis. Invest Ophthalmol Vis Sci  46:3502-3506.

  5. Ozerdem, U., and A.R. Hargens. 2005. A simple method for measuring interstitial fluid pressure in cancer tissues. Microvascular Research 70:116-120.

  6. Ozerdem, U. 2004. Targeting neovascular pericytes in neurofibromatosis type 1. Angiogenesis 7:307-311

  7. Rajantie, I., M. Ilmonen, A. Alminaite, U. Ozerdem, K. Alitalo, and P. Salven. 2004. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104:2084-2086.

  8. Ozerdem, U., and W.B. Stallcup. 2004. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 7:269-276.

  9. Ozerdem, U., and W.B. Stallcup. 2003. Early contribution of pericytes to angiogenic sprouting and tube formation. Angiogenesis 6:241-249.

  10. Song, M.K., S.P. Azen, A. Buley, F. Torriani, L. Cheng, S. Chaidhawangul, U. Ozerdem, B. Scholz, and W.R. Freeman. 2003. Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis. Am J Ophthalmol 136:696-702.

  11. Ozerdem, U., E. Monosov, and W.B. Stallcup. 2002. NG2 proteoglycan expression by pericytes in pathological microvasculature. Microvasc Res 63:129-134.

  12. Ozerdem, U., W.L. Charbono, and W.B. Stallcup. 2002. Plastic casting of embryonic, placental, and tumor vasculature in the mouse. Microvasc Res 64:486-490.

  13. Ozerdem, U., B. Mach-Hofacre, N. Varki, R. Folberg, A.J. Mueller, R. Ochabski, T. Pham, K. Appelt, and W.R. Freeman. 2002. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 24:86-91.

  14. Ozerdem, U., K.A. Grako, K. Dahlin-Huppe, E. Monosov, and W.B. Stallcup. 2001. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 222:218-227.

  15. Ozerdem, U., W.R. Freeman, D.U. Bartsch, and T.M. Clark. 2001. A simple noncontact wide-angle fundus photography procedure for clinical and research use. Retina 21:189-190.

  16. Ozerdem, U., B. Mach-Hofacre, K. Keefe, T. Pham, K. Soules, K. Appelt, and W.R. Freeman. 2001. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinases, on posttraumatic proliferative vitreoretinopathy. Ophthalmic Res 33:20-23.

  17. Ozerdem, U., and W.R. Freeman. 2001. Exudative retinal detachment following grid laser photocoagulation in a patient with hemiretinal vein occlusion. Eur J Ophthalmol 11:89-92.

  18. Ozerdem, U., B. Mach-Hofacre, L. Cheng, S. Chaidhawangul, K. Keefe, C.D. McDermott, G. Bergeron-Lynn, K. Appelt, and W.R. Freeman. 2000. The effect of prinomastat (AG3340), a potent inhibitor of matrix metalloproteinases, on a subacute model of proliferative vitreoretinopathy. Curr Eye Res 20:447-453.

  19. Ozerdem, U., L. Levi, L. Cheng, M.K. Song, C. Scher, and W.R. Freeman. 2000. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol 130:240-241.

  20. Cheng, L., W.R. Freeman, U. Ozerdem, M.K. Song, and S.P. Azen. 2000. Prevalence, correlates, and natural history of epiretinal membranes surrounding idiopathic macular holes. Virectomy for Macular Hole Study Group. Ophthalmology 107:853-859.

  21. Cheng, L., K.Y. Hostetler, S. Chaidhawangul, M.F. Gardner, U. Ozerdem, G. Bergeron-Lynn, B. Mach-Hofacre, A.J. Mueller, G.M. Severson, and W.R. Freeman. 1999. Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3- phosphonoformate. Retina 19:325-331.

  22. Kiratli, H., S. Bilgic, and U. Ozerdem. 1998. Management of massive orbital involvement of intraocular retinoblastoma. Ophthalmology 105:322-326.

  23. Kiratli, H., S. Bilgic, and U. Ozerdem. 1998. Retinoblastoma with acute lymphoblastic leukemia, polyposis coli, and multiple hamartomas. J Aapos 2:385-386.

  24. Virgintino D.*, U. Ozerdem*, F. Girolamo, L. Roncali, W. Stallcup, and R. Perris *Equally contributing authors. Reversal of cellular roles in Angiogenesis:Implications for anti-angiogenic therapy. Journal of Vascular Research  45:129-131.

[top]

 

  		 

Copyright © 2003. La Jolla Bioengineering Institute